CV Sciences operates two distinct divisions: pharmaceuticals and consumer products. These divisions are supported by our medical and scientific advisory board, and state-of-the art production facilities.

News Releases

News Releases

CV Sciences, Inc. to Exhibit and Present at the Mid-American Health Organization Expo and Summer Splash 2017 Convention

Company Continues its Expansion, Education, and Placement of its Leading Hemp-Derived Supplement Brand, PlusCBD Oil™, in the Natural Products Industry LAS VEGAS, NV–(Marketwired – July 18, 2017) – CV Sciences, Inc., (OTCQB: CVSI) (the “Company,” “CV Sciences,” “our” or “we”), preeminent supplier and manufacturer of hemp-derived CBD oil bulk and consumer products, today announced that its industry-dominating … Continue reading CV Sciences, Inc. to Exhibit and Present at the Mid-American Health Organization Expo and Summer Splash 2017 Convention

CV Sciences, Inc. Appoints Dr. Amy M. McCord as Director of Drug Development

Expert in Scientific and Regulatory Affairs to Assist Company on Regulatory path to Commercialization of Investigational Drug Candidate LAS VEGAS, NV – (Marketwired – July 11, 2017) – CV Sciences, Inc. (OTCQB: CVSI) (the “Company,” “CV Sciences,” “our” or “we”), announced today it has appointed Dr. Amy M. McCord, Ph.D., RAC as Director of Drug … Continue reading CV Sciences, Inc. Appoints Dr. Amy M. McCord as Director of Drug Development

CV Sciences, Inc. Reports Growing Clinical Evidence for Therapeutic Value of Pharmaceutical-Grade Cannabidiol (CBD)

Company Developing Prescription CBD for Smokeless Tobacco Addiction   LAS VEGAS, NV – (Marketwired – July 5, 2017) – CV Sciences, Inc. (OTCQB: CVSI) (the “Company,” “CV Sciences,” “our” or “we”), today provided an update on published outcomes of recent clinical research  on pharmaceutical-grade cannabidiol (CBD) pointing to its therapeutic potential as a prescription drug. In The New … Continue reading CV Sciences, Inc. Reports Growing Clinical Evidence for Therapeutic Value of Pharmaceutical-Grade Cannabidiol (CBD)

CV Sciences, Inc. to Exhibit and Present at the American Association of Naturopathic Physicians 2017 National Conference

Company Aims to Increase national Awareness and Continues to Expand its Distribution Network to Licensed Naturopathic Physicians   LAS VEGAS, NV – (Marketwired – June 27, 2017) – CV Sciences, Inc. (OTCQB: CVSI) (the “Company,” “CV Sciences,” “our” or “we”), today announced that its industry-dominating brand of hemp-derived cannabidiol oil finished products, PlusCBD Oil™, will be exhibiting at … Continue reading CV Sciences, Inc. to Exhibit and Present at the American Association of Naturopathic Physicians 2017 National Conference

CV Sciences, Inc.’s CEO Releases Letter to Stockholders and Customers Regarding Complaint filed by Securities and Exchange Commission

LAS VEGAS, NV–(Marketwired – June 19, 2017) – CV Sciences, Inc. (OTCQB: CVSI), (the “Company,” “CV Sciences,” “our” or “we”), today released a letter from Michael Mona, Jr., Chief Executive Officer, to stockholders and customers regarding a recent complaint filed by the Securities and Exchange Commission (the “SEC”): “Dear Stockholders and Customers, First, thank you … Continue reading CV Sciences, Inc.’s CEO Releases Letter to Stockholders and Customers Regarding Complaint filed by Securities and Exchange Commission

CV Sciences, Inc. Announces Commencement of IND Preparation Immediately Following Pre-IND Meeting with FDA

LAS VEGAS, NV – (Marketwired – June 19, 2017) – CV Sciences, Inc. (OTCQB: CVSI) (the “Company,” “CV Sciences,” “our” or “we”), today announced that it held its pre-IND meeting with the U.S. Food and Drug Administration (FDA) on June 15, 2017, to review its drug development plan for CVSI-007, the Company’s patent-pending product for … Continue reading CV Sciences, Inc. Announces Commencement of IND Preparation Immediately Following Pre-IND Meeting with FDA

CV Sciences, Inc. to Webcast Live at VirtualInvestorConferences.com June 1, 2017

Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com LAS VEGAS, NV – May 30, 2017 /PRNewswire/ — CV Sciences, Inc. (OTCQB: CVSI), today announced that Chief Financial Officer, Joseph Dowling, will present live at VirtualInvestorConferences.com on June 1, 2017. DATE: Thursday,  June 1, 2017 TIME: 11:30 AM EDT LINK: https://tinyurl.com/0601prepr … Continue reading CV Sciences, Inc. to Webcast Live at VirtualInvestorConferences.com June 1, 2017

CV Sciences, Inc. to Present at the 7th Annual LD Micro Invitational

LOS ANGELES, CA / ACCESSWIRE / May 23, 2017 / CV Sciences, Inc. (OTCQB: CVSI (the “Company,” “CV Sciences, “our,” or “we”) today announced that it will be presenting at the 7th annual LD Micro Invitational on Tuesday, June 6, at 1:00 PM PST / 4:00 PM EST. Joseph Dowling, Chief Financial Officer of CV Sciences, Inc., … Continue reading CV Sciences, Inc. to Present at the 7th Annual LD Micro Invitational

CV Sciences, Inc. Appoints Dr. Stephen M. Schmitz to its Board of Directors

Highly Regarded Pharma Veteran with Extensive Expertise in Drug Safety, Dietary Supplement Safety, Clinical Development and Regulatory Affairs LAS VEGAS, NV – (Marketwired – May 16, 2017) – CV Sciences, Inc. (OTCQB: CVSI) (“CV Sciences,” “our” or “we”), today announced the appointment of Stephen M. Schmitz, MD, MPH to its Board of Directors effective May … Continue reading CV Sciences, Inc. Appoints Dr. Stephen M. Schmitz to its Board of Directors

CV Sciences, Inc. Highlights WHO’s World No Tobacco Day – May 31, 2017

LAS VEGAS, NV – (Marketwired – May 8, 2017) – CV Sciences, Inc. (OTCQB: CVSI) (the “Company,” “CV Sciences,” “our” or “we”), is pleased to highlight the World Health Organization (WHO) and its partners in the annual World No Tobacco Day on May 31, 2017. The day notably features the health and risks associated with … Continue reading CV Sciences, Inc. Highlights WHO’s World No Tobacco Day – May 31, 2017